Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Objective: To evaluate the effects of hepatic impairment on the pharmacokinetics and safety of a single, oral axitinib dose in subjects with mild or moderate hepatic impairment. Methods: In this phase I, open-label, parallel-group study, a total of 24 subjects with either normal hepatic function (n ...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tortorici, Michael A., Toh, Melvin, Rahavendran, S. V., LaBadie, Robert R., Alvey, Christine W., Marbury, Thomas, Fuentes, Ernesto, Green, Matthew, Ni, Grace, Hee, Brian, Pithavala, Yazdi K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2010
Gaiak:
Phase I Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3171651/
https://ncbi.nlm.nih.gov/pubmed/20596748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9477-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak